Novogenia AG (MUN:7V0)

Market Cap	71.40M -18.5%
Revenue (ttm)	54.30M -59.2%
Net Income	545.47K -97.7%
EPS	0.05 -97.7%
Shares Out	12.00M
PE Ratio	130.90
Forward PE	n/a
Dividend	0.56 (9.45%)
Ex-Dividend Date	Jun 29, 2026

Volume	n/a
Open	5.95
Previous Close	5.95
Day's Range	5.95 - 5.95
52-Week Range	5.70 - 11.80
Beta	0.31
Analysts	Strong Buy
Price Target	19.38 (+225.71%)
Earnings Date	Sep 8, 2026

About Novogenia AG

Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2021
• Employees: 204
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: 7V0

Financial Performance

In 2025, Novogenia AG's revenue was 54.30 million, an increase of 98.53% compared to the previous year's 27.35 million. Earnings were 545,469, a decrease of -97.04%.

Analyst Summary

According to 2 analysts, the average rating for 7V0 stock is "Strong Buy." The 12-month stock price target is €19.38, which is an increase of 225.71% from the latest price.

Price Target

€19.38

(225.71% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 5, 2026

Data Sources Report a data error